Table 1

Patients characteristics
Characteristic

Total

(n = 50)

Adverse event

(n = 27)

Event-free survival

(n = 23)

p-value
Age, (years ± SD) 57 ± 17 52 ± 16 62 ± 16
Male / Female (n) 36 / 14 18 / 9 18 / 5
Charlson Comorbidity Score age adjusted
(Median, interquartile range) 1 [0 – 4] 1 [0 – 4] 0 [0 – 4,5] 0.89
Diabetes Mellitus (n) 8 6 2 0.19
Immunocompromised* (n) 1 1 0 --
i.v. Drug Abuse (n) 6 6 0 0.02
Conditions at diagnosis (n)
Vasopressors 15 12 3 0.02
Mechanical ventilation 11 8 3 0.16
ICU 17 12 5 0.09
Site of infection (n, %)
Aortic valve 29 (58%) 13 16 0.58
Pulmonary valve 1 (2%) 1 0 --
Mitral valve 14 (28%) 8 6 0.59
Tricuspid valve 6 (12%) 5 1 --
Prosthetic valve (n) 11 8 3 0.16
Known valvular disease (n) 13 7 6 1
Echocardiography
Perivalvular abscedation (n) 5 4 1 0.22
Severe Insufficiency (n) 21 8 13 0.05
Size of vegetation
(2D, mm2, median, interquartile range) 103 [32 – 179] 105 [54 – 195] 98 [27 – 162] 0.22
Causative organism (n, %)
Staphylococcus aureus 16 (32%) 15 1 < 0.01
Staphylococci other than aureus 7 (14%) 2 0 --
B-Streptococci 2 (4%) 0 2 --
Streptococci other than B 11 (22%) 2 9 0.03
Enterococcus faecium 5 (10%) 2 3 --
Actinomyces israelii 1 (2%) 0 1 --
No proven causative organism 7 (14%) 4 0 --

Data are presented as number of cases (percentages of total number).

*Patients with human immunodeficiency virus, acquired immunodeficiency syndrome, solid organ or bone marrow transplantation, receiving steroids (>20 mg of prednisone or equivalent for >1 month), or recent chemotherapy (>1 month).

Cornelissen et al.

Cornelissen et al. BMC Infectious Diseases 2013 13:272   doi:10.1186/1471-2334-13-272

Open Data